» Articles » PMID: 36182714

Pathogenic MtDNA Variants, in Particular Single Large-scale MtDNA Deletions, Are Strongly Associated with Post-lingual Onset Sensorineural Hearing Loss in Primary Mitochondrial Disease

Abstract

In this retrospective cohort study of 193 consecutive subjects with primary mitochondrial disease (PMD) seen at the Children's Hospital of Philadelphia Mitochondrial Medicine Frontier Program, we assessed prevalence, severity, and time of onset of sensorineural hearing loss (SNHL) for PMD cases with different genetic etiologies. Subjects were grouped by genetic diagnosis: mitochondrial DNA (mtDNA) pathogenic variants, single large-scale mtDNA deletions (SLSMD), or nuclear DNA (nDNA) pathogenic variants. SNHL was audiometrically confirmed in 27% of PMD subjects (20% in mtDNA pathogenic variants, 58% in SLSMD and 25% in nDNA pathogenic variants). SLSMD had the highest odds ratio for SNHL. SNHL onset was post-lingual in 79% of PMD cases, interestingly including all cases with mtDNA pathogenic variants and SLSMD, which was significantly different from PMD cases caused by nDNA pathogenic variants. SNHL onset during school age was predominant in this patient population. Regular audiologic assessment is important for PMD patients, and PMD of mtDNA etiology should be considered as a differential diagnosis in pediatric patients and young adults with post-lingual SNHL onset, particularly in the setting of multi-system clinical involvement. Pathogenic mtDNA variants and SLSMD are less likely etiologies in subjects with congenital, pre-lingual onset SNHL.

Citing Articles

Hearing Impairment and Neuroimaging Results in Mitochondrial Diseases.

Cadoni G, Primiano G, Picciotti P, Calandrelli R, Galli J, Servidei S J Pers Med. 2023; 13(9).

PMID: 37763097 PMC: 10532611. DOI: 10.3390/jpm13091329.


The Role of Primary Mitochondrial Disorders in Hearing Impairment: An Overview.

Fancello V, Fancello G, Palma S, Monzani D, Genovese E, Bianchini C Medicina (Kaunas). 2023; 59(3).

PMID: 36984609 PMC: 10058207. DOI: 10.3390/medicina59030608.

References
1.
Stewart J, Chinnery P . The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet. 2015; 16(9):530-42. DOI: 10.1038/nrg3966. View

2.
Greaves L, Reeve A, Taylor R, Turnbull D . Mitochondrial DNA and disease. J Pathol. 2011; 226(2):274-86. DOI: 10.1002/path.3028. View

3.
Dvorakova V, Kolarova H, Magner M, Tesarova M, Hansikova H, Zeman J . The phenotypic spectrum of fifty Czech m.3243A>G carriers. Mol Genet Metab. 2016; 118(4):288-95. DOI: 10.1016/j.ymgme.2016.06.003. View

4.
Parikh S, Goldstein A, Karaa A, Koenig M, Anselm I, Brunel-Guitton C . Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2017; 19(12). PMC: 7804217. DOI: 10.1038/gim.2017.107. View

5.
von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View